Dermatology Drugs Market - Industry Analysis, Size, Share To 2026

Polaris Market Research presents a most up-to-date research on "Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022".

Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high-priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

Request a sample report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-free-sample

Major Key Player in the Report are:

• Allergan Plc
• Valeant Pharmaceuticals
• Dermira Inc
• Aclaris Therapeutics, Inc
• AnaptysBio, Inc
• Revance Therapeutics
• Foamix Pharmaceuticals
• Novan, Inc
• Sienna Biopharmaceuticals
• Pfizer
• Sanofi
• Galderma
• Leo Pharma
• Roviant Sciences

• Otsuka Pharmaceuticals.

Currently, the Dermatology Drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

Dermatology Drugs Market, by Region:

North America - U.S., Canada

Europe - Germany, UK, France

Asia-Pacific – India, Japan, China

Latin America - Brazil, Mexico

Middle East & Africa

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

• Market Analysis by Dermatology Key Indications
• Market Analysis by Treatment Class/Marketed Drugs
• Market Analysis by Regions.

The Marketed Therapies undertaken in forecast from 2016-2022 are:

• etanercept; Enbrel
• infliximab; Remicade
• adalimumab; Humira
• ustekinumab; Stelara
• secukinumab; Cosentyx
• ixekizumab; Taltz
• golimumab; Simponi
• brodalumab; Siliq
• guselkamab; Tremfya
• Topical Drugs
• Oral Antibiotics

The Major Indications in Dermatology Therapy area:

• Atopic Dermatitis
• Psoriasis
• Acne
• Rosacea.

  Out of all dermatological indications, Psoriasis is the largest with several approved biologics and followed by Acne. Psoriasis affects approximately 8 million patients in the U.S. and roughly 20-30% have moderate to severe psoriasis. Out of them, only 10% of the moderate to severe patients are treated with biologics. Acne is the most commonly treated skin disorders and occurs in adolescents and patients between 15-24 years of age. Despite the size of the market, there is no single best treatment for acne and therefore combinations treatments are often used. Currently, Topical therapies dominate the acne treatment. There remains significant unmet need in the Dermatology drugs market as current treatment options do not offer improved safety, efficacy and tolerability profile often with low patient compliance.

  Read More Details @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.